感染

订阅

MedSci主页 / 所有栏目 / 感染

大剂量吸入一氧化氮治疗COVID-19肺部并发症的临床试验：将在加拿大进行

2020-04-02 Allan MedSci原创

一氧化氮COVID-19肺炎
关注

全球生物制药公司Mallinckrodt和Novoteris今日宣布，加拿大卫生部已批准吸入性一氧化氮（gNO）治疗COVID-19肺炎的临床试验。

全球生物制药公司Mallinckrodt和Novoteris今日宣布，加拿大卫生部已批准吸入性一氧化氮（gNO）治疗COVID-19肺炎的临床试验，旨在研究Thiolanox®（一种大剂量吸入一氧化氮疗法）的有效性和安全性。这款研究性疗法将使用Novoteris的吸入一氧化氮输送装置（INODD）和Mallinckrodt的高浓度5000 PPM一氧化氮气体。Mallinckrodt和Novoteris公司期望在未来几天内开始招募患者。

Mallinckrodt的执行副总裁兼首席科学官史蒂芬·罗曼诺说：“吸入一氧化氮可能具有抗病毒作用，并能改善COVID-19患者的氧合作用和肺动脉压力。我们很荣幸能与Novoteris合作进行这项临床试验，并致力于抗击这种前所未有的疫情”。

 

原始出处：

https://www.firstwordpharma.com/node/1712451?tsid=4

版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (5)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1758225, encodeId=af5e1e58225f9, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 21 16:53:27 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312647, encodeId=389e131264ec8, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337391, encodeId=38ab133e39106, content=<a href='/topic/show?id=96fd19358fa' target=_blank style='color:#2F92EE;'>#一氧化氮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19358, encryptionId=96fd19358fa, topicName=一氧化氮)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545235, encodeId=fe2e15452351d, content=<a href='/topic/show?id=93c682342bb' target=_blank style='color:#2F92EE;'>#肺部并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82342, encryptionId=93c682342bb, topicName=肺部并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a8513702341, createdName=644982816_68283325, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578697, encodeId=65f115e8697ca, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=)]
    2020-07-21 丁鹏鹏

    #并发#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1758225, encodeId=af5e1e58225f9, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 21 16:53:27 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312647, encodeId=389e131264ec8, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337391, encodeId=38ab133e39106, content=<a href='/topic/show?id=96fd19358fa' target=_blank style='color:#2F92EE;'>#一氧化氮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19358, encryptionId=96fd19358fa, topicName=一氧化氮)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545235, encodeId=fe2e15452351d, content=<a href='/topic/show?id=93c682342bb' target=_blank style='color:#2F92EE;'>#肺部并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82342, encryptionId=93c682342bb, topicName=肺部并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a8513702341, createdName=644982816_68283325, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578697, encodeId=65f115e8697ca, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=)]
    2020-04-04 shanyongle

    #加拿大#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1758225, encodeId=af5e1e58225f9, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 21 16:53:27 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312647, encodeId=389e131264ec8, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337391, encodeId=38ab133e39106, content=<a href='/topic/show?id=96fd19358fa' target=_blank style='color:#2F92EE;'>#一氧化氮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19358, encryptionId=96fd19358fa, topicName=一氧化氮)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545235, encodeId=fe2e15452351d, content=<a href='/topic/show?id=93c682342bb' target=_blank style='color:#2F92EE;'>#肺部并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82342, encryptionId=93c682342bb, topicName=肺部并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a8513702341, createdName=644982816_68283325, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578697, encodeId=65f115e8697ca, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=)]
    2020-04-04 ms7474195563676018

    #一氧化氮#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1758225, encodeId=af5e1e58225f9, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 21 16:53:27 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312647, encodeId=389e131264ec8, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337391, encodeId=38ab133e39106, content=<a href='/topic/show?id=96fd19358fa' target=_blank style='color:#2F92EE;'>#一氧化氮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19358, encryptionId=96fd19358fa, topicName=一氧化氮)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545235, encodeId=fe2e15452351d, content=<a href='/topic/show?id=93c682342bb' target=_blank style='color:#2F92EE;'>#肺部并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82342, encryptionId=93c682342bb, topicName=肺部并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a8513702341, createdName=644982816_68283325, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578697, encodeId=65f115e8697ca, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=)]
    2020-04-04 644982816_68283325

    #肺部并发症#

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1758225, encodeId=af5e1e58225f9, content=<a href='/topic/show?id=84ba49031f9' target=_blank style='color:#2F92EE;'>#并发#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=49031, encryptionId=84ba49031f9, topicName=并发)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=a27e37327108, createdName=丁鹏鹏, createdTime=Tue Jul 21 16:53:27 CST 2020, time=2020-07-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1312647, encodeId=389e131264ec8, content=<a href='/topic/show?id=1aa333006b4' target=_blank style='color:#2F92EE;'>#加拿大#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=33006, encryptionId=1aa333006b4, topicName=加拿大)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=279b407, createdName=shanyongle, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1337391, encodeId=38ab133e39106, content=<a href='/topic/show?id=96fd19358fa' target=_blank style='color:#2F92EE;'>#一氧化氮#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=51, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=19358, encryptionId=96fd19358fa, topicName=一氧化氮)], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTKjqGDO7icVKUiaT7urgwXvnvzWtp0fMFU46Xfib8oavFKygiaWtibXReS6ZUh3PImsNicGAwTO5HXxoicnA/132, createdBy=ee262500130, createdName=ms7474195563676018, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1545235, encodeId=fe2e15452351d, content=<a href='/topic/show?id=93c682342bb' target=_blank style='color:#2F92EE;'>#肺部并发症#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=44, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=82342, encryptionId=93c682342bb, topicName=肺部并发症)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=7a8513702341, createdName=644982816_68283325, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1578697, encodeId=65f115e8697ca, content=<a href='/topic/show?id=fbf0436148a' target=_blank style='color:#2F92EE;'>#大剂量#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=43614, encryptionId=fbf0436148a, topicName=大剂量)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=cd6a16418535, createdName=ms7899726347904398, createdTime=Sat Apr 04 11:53:27 CST 2020, time=2020-04-04, status=1, ipAttribution=)]
    2020-04-04 ms7899726347904398

    #大剂量#

    0

相关资讯

Clin Respir J：哮喘和过敏性鼻炎儿童中与呼出一氧化氮相关的因素研究

导致呼出一氧化氮（FeNO）水平变化的相关因素在不同年龄段的哮喘儿童中仍具缺乏报道。最近，有研究人员在具有过敏性鼻炎的哮喘儿童中评估了与FeNO相关的因素和FeNO对吸入性类固醇的响应情况。研究包括了5岁到12岁的哮喘儿童。研究人员测试了FeNO、肺功能和对乙酰甲胆硷的支气管高反应性（BHR）、气源性过敏原的皮刺测试、血清中总免疫球蛋白E（T-lgE）和血液中的嗜酸性粒细胞水平，并评估了FeNO与

Adv Med Sci：药物治疗对永久过敏性鼻炎患者的鼻呼出一氧化氮（NO）影响研究

最近，有研究人员评估了鼻一氧化氮（NO）在治疗永久过敏性鼻炎（PER）患者中的作用。研究是一个随机和比较性的研究。研究的受试者包括对照（健康对照）和PER患者。研究人员搜集了所有的临床、功能和生物学数据进行分析，并电致发光设备测量了呼出NO组分（FENO）。PER患者随机的进行抗组胺结合白三烯素阻断剂（LRA）治疗或者单独鼻内类固醇治疗（INS）。研究持续的时间为2年，包括了501名受试者：234

Int Arch Allergy Immunol：鼻腔炎症疾病学龄前儿童鼻一氧化氮浓度的临床意义研究

过敏性鼻炎是鼻呼吸道的一种过敏性炎症，并且慢性鼻窦炎是鼻窦炎症疾病。该疾病可以通过感染、过敏或者自身免疫问题诱导产生。这两种疾病的诊断主要是通过临床症状，过敏原测试和成像来诊断。过敏原测试是非侵入的但较为昂贵。成像测试对儿童来讲较为困难。鼻一氧化氮（NNO）的测量时非侵入的，且没有辐射，花费较少。最近，有研究人员评估了NNO在鼻炎症疾病学龄前儿童中的临床意义。研究包括了55名过敏性鼻炎儿童，包括了

Adv Med Sci：哮喘和过敏性鼻炎儿童上呼吸道鼻一氧化氮研究

最近，有研究人员在患有呼吸道疾病的儿科患者中比较了鼻一氧化氮（nNO）水平。研究包括了179名年龄在7-15岁的患有哮喘、过敏性鼻炎或者哮喘和过敏性鼻炎的患者，研究还包括了从当地过敏诊所招募的健康对照。研究人员评估了nNO水平与患者的临床参数之间的关系。研究发现，nNO水平在过敏性鼻炎患者（2316.3±442.33 ppb， p<0.001）中和哮喘和过敏性鼻炎（2399.9±446.73

J Asthma：FeNO和MMEF在预测患有或者不患有过敏性鼻炎慢性咳嗽患者中的咳嗽变异性哮喘中的诊断价值分析

最近，有研究人员评估了呼出气中一氧化氮浓度（FeNO）和最大中段呼气流速（MMEF）在患有或者不患有过敏性鼻炎慢性咳嗽患者中区分咳嗽变异性哮喘（CVA）的诊断价值情况。研究总共包括了328名慢性咳嗽患者，且经历了呼吸量测试和FeNO测试。研究人员根据CVA诊断标准将患者分成了两个小组，CVA组（n=125）和NCVA（n=203）组。研究发现，FeNO和MMEF从慢性咳嗽中区分CVA的最优FeNO

J Allergy Clin Immunol Pract：鼻一氧化氮在过敏性鼻炎诊断中的使用研究

鼻NO（nNO）已经在患有鼻息肉或者不患有鼻息肉的慢性鼻窦炎患者中评估过。然而，nNO水平在过敏性鼻炎（AR）和非过敏性鼻炎（NAR）中在之前的研究中存在冲突的结果。最近，有研究人员评估了nNO在诊断AR和NAR中的价值，以及鼻窦炎（SI）存在与否的影响情况。研究共包括了173名连续性的患者和46名正常的对照（NCs）。其中，94名患者诊断为AR，79名诊断为NAR。研究发现，在AR患者和NCs中

拓展阅读

Ann Maxillofac Surg：补充一氧化氮对牙种植后唾液中白细胞介素- 6水平的影响

本研究的目的是评估和比较补充一氧化氮(NO)的患者种植牙前后唾液白细胞介素-6 (IL-6)的水平。

Int J Clin Pediatr Dent：儿童龋齿治疗前后唾液一氧化氮水平的比较研究

评估治疗前儿童龋齿患者的唾液一氧化氮(NO)水平，并比较治疗前、治疗后15天和30天的唾液一氧化氮水平。

新研究：高剂量吸入一氧化氮在新冠肺炎导致的急性低氧性呼吸衰竭

与因新冠肺炎导致急性低氧性呼吸衰竭的成年人的常规护理相比，使用高剂量吸入一氧化氮在48小时内改善了PaO2/FiO2。

Journal of Liver Transplantation：用吸入一氧化氮治疗正位肝移植期间的肺动脉高压

术中血管扩张疗法，包括iNO，可能是一种有用的治疗和诊断工具。有必要进一步调查肝移植中新PH的围手术期管理，以完善手术决策并改善患者结果。

吸入一氧化氮在慢性阻塞性肺疾病中的应用

本研究旨在调查通过鼻导管给予氧依赖型慢性阻塞性肺病患者 24 小时的一氧化氮 (NO) 和氧气混合物的安全性和有效性。

Cardiol Young：在家吸入一氧化氮治疗患有肺动脉高压并伴有术后肺静脉阻塞的儿童

尽管心血管手术近年来取得了进展，但有17%的患者会发展出术后肺静脉阻塞，这与较高的死亡率和发病率相关。术后肺静脉阻塞引起的肺动脉高压有时包括术前和术后毛细血管肺高压。